1. Market Research
  2. > Pharmaceutical
  3. > Biopharmaceutical Market Trends
Global CAR T-Cell Therapy Market: Focus on Product, Mechanism, Application, Target Antigen, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

Global CAR T-Cell Therapy Market: Focus on Product, Mechanism, Application, Target Antigen, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

  • November 2020
  • 266 pages
  • ID: 5989634
  • Format: PDF
  • BIS Research

Summary

Table of Contents

Global CAR T-Cell Therapy Market to Grow at a CAGR of 44.79% from 2020-2030

Market Report Coverage - CAR T-Cell Therapy

Market Segmentation

• Therapy Application – Diffuse large B-cell lymphoma (DLBCL), Acute lymphoblastic leukemia (ALL), Multiple myeloma (MM), Chronic lymphocytic leukemia (CLL), Follicular lymphoma (FL), Mantle cell lymphoma (MCL), and other cancers or indications
• Target Antigen – CD19/CD22, BCMA (B-cell maturation antigen), and others target antigens

Regional Segmentation

• North America – U.S., Canada
• Europe – Germany, France, Italy, U.K., Spain, and Rest-of-Europe
• Asia-Pacific – China, Japan, India, South Korea, Australia, and Rest-of-Asia-Pacific (RoAPAC)
• Latin America – Brazil, Mexico, and Rest-of-the-Latin America
• Rest-of-the-World

Growth Drivers

• Rising Number of Patients with Hematologic Cancers
• Dramatic Rise in Global CAR T-Cell Trials
• Landmark Approvals of CAR T-Cell Therapies by the U.S. FDA and the EMA

Market Challenges

• High Treatment Cost of CAR T-Cell Therapy
• Side Effects of CAR T-Cell Therapy

Market Opportunities

• Opportunities for Immunotherapy

Key Companies Profiled

Amgen, Inc., Autolus Therapeutics plc., Bellicum Pharmaceuticals, Inc., Bluebird Bio Inc., Bristol-Myer Squibb, CARsgen Therapeutics, Ltd., Cartesian Therapeutics, Inc., Cellectis S.A., Celyad Oncology SA, Fortress Biotech, Inc., Janssen Pharmaceuticals, Inc., Kite Pharma, Inc., Legend Biotech Corporation, Novartis AG, and Pfizer, Inc.

Key Questions Answered in this Report:
• What is a CAR T-cell?
• How are CAR T-cells developed?
• What are the various indications targeted using CAR T-cell therapies?
• What are the various CAR T-cell therapies available in the market?
• What are the emerging CAR T-cell therapies for the treatment of hematologic cancers?
• How does the pipeline for the global CAR T-cell therapy market look like?
• What is the current market size and future potential of these CAR T-cell therapies?
• What are the major market drivers, challenges, and opportunities in the global CAR T-cell therapy market?
• What is the mechanism of action of various CAR T-cell therapies available in the market?
• What mechanisms of action and molecules are being trialed the most in pipeline products?
• What are the target antigens in CAR T-cell therapy?
• How does the clinical trial landscape look for the global CAR T-cell therapy market?
• What is the patent landscape of this market? What will be the impact of patent expiry on this market?
• What is the price structure of CAR T-cell products?
• What is the total cost of treating a patient with CAR T-cell therapy?
• What will be the impact of COVID-19 on this market?
• What are the guidelines implemented by different government bodies to regulate the approval of CAR T-cell therapy?
• What are the reimbursement scenario and regulatory structure for CAR T-cell therapy?
• What are the challenges faced by manufacturers in CAR T-cell therapy development?
• What are the key technological developments on which the current industry leaders are spending a major share of their research and development (R&D) investments?
• Which are the leading players currently holding dominating shares in the global CAR T-cell therapy market?
• What are the key strategies incorporated by the players of the global CAR T-cell therapy market to sustain the competition and retain their supremacy?
• What is the current revenue contribution of the global CAR T-cell therapy market (by application type), and how is it expected to evolve in the forecast period?
• What is the current revenue contribution of the global CAR T-cell therapy market (by target antigen), and how is it expected to evolve in the forecast period?
• Which region is expected to contribute the highest revenue to the global CAR T-cell therapy market during the forecast period?

Market Overview

The scientific community has been pursuing research for the development of CAR T-cell therapy for over a century.Immunotherapy has emerged as an innovative treatment option over decades, as it harnesses the patient’s immune system to attack cancer.

The global market for CAR T-cell therapy is predicted to grow at a CAGR of 44.79% over the forecast period 2020-2030. The market is driven by certain factors, which include increasing global geriatric population, increasing number of lymphoma and leukemia cases, rising number of relapsed or refractory cancer cases showing response failure to alternative treatments such as chemotherapy and radiation therapy, focus on research and development of novel immunotherapies, and strong product pipeline of global CAR T-cell therapy.

The market is favored by the development of CAR T-cell therapy for several clinical areas such as diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and other cancers or indications. The increase in the geriatric population and the increasing number of lymphoma and leukemia cases across the globe are expected to translate into a significantly higher demand for the CAR T-cell therapy market.

Furthermore, the companies are investing huge amounts in research and development of CAR T-cell therapy either as a monotherapy or as combination therapy. The clinical trial landscape of various hematologic cancers has been on the rise in recent years, and this will fuel the CAR T-cell therapy market in the future.

Within the research report, the market is segmented based on application, target antigen, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel CAR T-cell therapy. Due to the diverse product portfolio and intense market penetration, Novartis AG. has been a pioneer in this field and has been a significant competitor in this market.

The pharmaceutical leading manufacturer, Kite Pharma, Inc. (a Gilead Company), has launched its CAR T-cell therapies into the market such as Yescarta (axicabtagene ciloleucel), and Tecartus (brexucabtagene autoleucel) to compete with Novartis AG’s Kymriah (tisagenlecleucel) therapy market dominance.

Based on region, North America holds the largest share of the CAR T-cell therapy market due to improved healthcare infrastructure, rise in per capita income, early availability of approved therapies, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Countries Covered
• North America
• U.S.
• Canada
• Europe
• Germany
• France
• Spain
• U.K.
• Italy
• Rest-of-Europe
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Rest-of-Asia-Pacific
• Latin America
• Brazil
• Mexico
• Rest-of-Latin America
• Rest-of-the-World

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Cancer Stem Cells Industry

  • $ 5600
  • April 2021
  • 282 pages

Abstract: - Global Cancer Stem Cells Market to Reach $1.7 Billion by 2027 - Amid the COVID-19 crisis, the global market for Cancer Stem Cells estimated at US$963 Million in the year 2020, is projected ...

  • World
  • China
  • Immunotherapy
  • Industry analysis

Global Beta-Glucan Industry $ 5450 April 2021


ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on